ATIC
Bifunctional purine biosynthesis protein ATIC
Also known as: AICARFT, IMPCHASE, PUR9_HUMAN, PURH
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P31939
- Gene
- ATIC
- Ensembl
- ENSG00000138363
- Chromosome
- 2
- Canonical length
- 592 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Plasma membrane,Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a bifunctional protein that catalyzes the last two steps of the de novo purine biosynthetic pathway. The N-terminal domain has phosphoribosylaminoimidazolecarboxamide formyltransferase activity, and the C-terminal domain has IMP cyclohydrolase activity. A mutation in this gene results in AICA-ribosiduria. [provided by RefSeq, Sep 2009]
Canonical amino-acid sequenceUniProt
592 residues, UniProt reviewed canonical sequence.
>P31939|ATIC
1 MAPGQLALFS VSDKTGLVEF ARNLTALGLN LVASGGTAKA LRDAGLAVRD VSELTGFPEM
61 LGGRVKTLHP AVHAGILARN IPEDNADMAR LDFNLIRVVA CNLYPFVKTV ASPGVTVEEA
121 VEQIDIGGVT LLRAAAKNHA RVTVVCEPED YVVVSTEMQS SESKDTSLET RRQLALKAFT
181 HTAQYDEAIS DYFRKQYSKG VSQMPLRYGM NPHQTPAQLY TLQPKLPITV LNGAPGFINL
241 CDALNAWQLV KELKEALGIP AAASFKHVSP AGAAVGIPLS EDEAKVCMVY DLYKTLTPIS
301 AAYARARGAD RMSSFGDFVA LSDVCDVPTA KIISREVSDG IIAPGYEEEA LTILSKKKNG
361 NYCVLQMDQS YKPDENEVRT LFGLHLSQKR NNGVVDKSLF SNVVTKNKDL PESALRDLIV
421 ATIAVKYTQS NSVCYAKNGQ VIGIGAGQQS RIHCTRLAGD KANYWWLRHH PQVLSMKFKT
481 GVKRAEISNA IDQYVTGTIG EDEDLIKWKA LFEEVPELLT EAEKKEWVEK LTEVSISSDA
541 FFPFRDNVDR AKRSGVAYIA APSGSAADKV VIEACDELGI ILAHTNLRLF HHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ATIC can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 49 nTPM
Expression across tissuesHPA
Tissue
- tonsil: 49 nTPM
- rectum: 45 nTPM
- skeletal muscle: 44 nTPM
- lymph node: 42 nTPM
- thymus: 39 nTPM
- seminal vesicle: 36 nTPM
Single-cell type
- migrating cytotrophoblasts: 239 nCPM
- cytotrophoblasts: 214 nCPM
- extravillous trophoblasts: 199 nCPM
- syncytiotrophoblasts: 107 nCPM
- erythrocyte progenitors: 81 nCPM
- decidual stromal cells: 81 nCPM
Immune cell
- MAIT T-cell: 59 nTPM
- memory B-cell: 57 nTPM
- NK-cell: 56 nTPM
- memory CD8 T-cell: 54 nTPM
- T-reg: 50 nTPM
- naive CD4 T-cell: 50 nTPM
Brain region
- white matter: 54 nTPM
- pons: 47 nTPM
- basal ganglia: 47 nTPM
- thalamus: 47 nTPM
- cerebral cortex: 46 nTPM
- midbrain: 44 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ATIC.
Disease | AllUniProt
Conditions ATIC is implicated in, by any mechanism.
- AICA-ribosuria due to ATIC deficiency (AICAR) MIM:608688
Disease | GeneticClinVar
9 pathogenic / likely-pathogenic of 197 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- AICA-ribosiduria
Disease | ImmuneIEDB
Conditions an epitope on ATIC was assayed in.
- melanoma T cell
- skin melanoma T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.25
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.48
- DepMap mean gene effect
- -0.35
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 'de novo' AMP biosynthetic process
- 'de novo' IMP biosynthetic process
- 'de novo' XMP biosynthetic process
- animal organ regeneration
- brainstem development
- cellular response to interleukin-7
- cerebellum development
- cerebral cortex development
- dihydrofolate metabolic process
- GMP biosynthetic process
- nucleobase-containing compound metabolic process
- tetrahydrofolate biosynthetic process
Molecular functions
- cadherin binding
- protein homodimerization activity
- IMP cyclohydrolase activity
- phosphoribosylaminoimidazolecarboxamide formyltransferase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Methylglyoxal synthase-like domain
- Cytidine deaminase-like
- Methylglyoxal synthase-like domain superfamily
- MGS-like domain
- Bifunctional purine biosynthesis protein PurH-like
- AICAR transformylase, insert domain superfamily
- AICAR transformylase, duplicated domain superfamily
- AICARFT/IMPCHase bienzyme
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ATIC in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ATIC as an antibody target. Whether an autoantibody or antibody against ATIC could matter depends on whether native ATIC is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ATIC is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ATIC as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...